# US 2010/0168092 A1 · Pharmaceutical composition with anti-diabetic action

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168092 A1
- Document ID: US20100168092A1
- Status: Published application
- Kind: A1
- Application number: 12/673,243
- Filed: 2008-05-22
- Published: 2010-07-01
- Earliest claimed: 2007-09-14
- Assignees: Zakrytoe Artsinonemoe Obschesto "Masterclone"
- Inventors: Alexander Victorovich Demin; Vitaly Afanasievich Martianov; Alexander Mihaylovich Shuster
- Web page: https://patentgrep.com/patent/US20100168092A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to medicine, in particular to searching and developing novel medicinal agent for treating pancreatic diabetes. The invention is based on the development of more effective and less toxic medicinal agents based on indole derivatives which exhibit antidiabetic, hypolipidemic, hypoglycemic, hypocholesterolemic activity and insulin resistance-improving actions and the structure of which differs from the structure of traditionally used compounds. The inventive indole derivatives are also low-toxic and easily tolerated.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A method for the treatment or prophylaxis of diabetes, comprising administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a compound of general formula (I):
where:
R1 is selected from the group consisting of an optionally substituted alkyl, an optionally substituted oxyalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclil, and an optionally substituted aryl, wherein the optional substituent(s) may be one or more members selected from lower alkyl, halogen, oxyalkyl, hydroxyl, and amino;
R2 is —H, or —CH2NR′R″; where R′ and R″, independently of each other, are each selected from the group consisting of hydrogen, optionally substituted alkene, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocyclil, and optionally substituted aryl, or where R′ and R″, along with the nitrogen atom with which they are bound, form guanidyl or optionally substituted azaheterocyclil;
R3 is an alkoxy group, or —OH;
or R2 and R3 form together an optionally substituted oxazine cycle;
R4 is selected from the group consisting of hydrogen, halogen, cyano, NO2, trifluoromethyl, optionally substituted aryl and optionally substituted heterocyclil;
A represents —S—, —SO—, —SO2—, and n=0-1;
B represents —(CH2)k—R5, where k=0-2, and where R5 is an optionally substituted aryl, an optionally substituted alkyl, an optionally substituted oxyalkyl, or an optionally substituted heterocyclil, or where R5 represents a substituent of the type:
where Rn1 and Rn2 are defined according to the definitions of the substituents R′ and R″above;
or hydrates and/or pharmaceutically acceptable salts thereof.

### Claim 28 (depends on 27)

A method according to claim 27, wherein the compound of formula (I) is the 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-bromoindole hydrochloride represented by the following formula:
*HCI*H2O.

### Claim 29 (depends on 27)

A method according to claim 27, wherein the compound of formula (I) is the 1-methyl-2-pyrrolidinyl-1-methyl-3-carbethoxy-5-hydroxy-6-(pyridine-3-yl) indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 30 (depends on 27)

A method according to claim 27, wherein the compound of formula (I) is the 1-methyl-2-pyrrolidinomethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-(pyridine-3-yl) indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 31 (depends on 27)

A method according to claim 27, wherein the compound of formula (I) is the 1-methyl-2-dimethylaminomethyl-3-carbethoxy-4-pyrrolidinomethyl-5-hydroxy-6 (pyridine-3-yl) indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 32 (depends on 27)

A method according to claim 27, wherein the compound of formula (I) is the methyl-2-B-naphthylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-bromo indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 33 (depends on 27)

A method according to claim 27, wherein the compound of formula (I) is the 9-carbethoxy-2,7-dimethyl-5-pyridine-3-yl-8-[(pyrrolidin-1-yl)methyl]-1,2,3,7-tetrahydro[1,3]oxazino[5,6-e]indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 34 (depends on 27)

A method according to claim 27, wherein the compound of formula (I) is selected from the group consisting of:
1-methyl-2-phenylsulfomethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-bromoindole,
1-methyl-2-phenylsulfoxymethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-bromoindole,
1-methyl-2-phenylsulfomethyl-3-carbethoxy-5-hydroxy-6-bromoindole,
1-methyl-2-phenylsulfoxymethyl-3-carbethoxy-5-hydroxy-6-bromoindole,
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 35 (depends on 27)

A method according to claim 27 wherein said pharmaceutical composition is administered in the form of tablets, granules, capsules, suspensions, solutions or injections.

### Claim 36 (depends on 27)

A method according to claim 27 wherein said pharmaceutical composition includes one or more pharmaceutically acceptable carriers and/or excipients.

### Claim 37

A method of preparing a pharmaceutical composition effective for treating diabetes, comprising formulating a compound of general formula I with one or more pharmaceutically acceptable carriers or excipients; wherein said compound of general formula (I) is:
where:
R1 is selected from the group consisting of an optionally substituted alkyl, an optionally substituted oxyalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclil, and an optionally substituted aryl, wherein the optional substituent(s) may be one or more members selected from lower alkyl, halogen, oxyalkyl, hydroxyl, and amino;
R2 is —H or —CH2NR′R″, where R′ and R″, independently of each other, are each selected from the group consisting of hydrogen, optionally substituted alkene, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocyclil, and optionally substituted aryl, or where R′ and R″, along with the nitrogen atom with which they are bound, form guanidyl or optionally substituted azaheterocyclil;
R3 is an alkoxy group or —OH;
or where R2 and R3 form together an optionally substituted oxazine cycle;
R4 is selected from the group consisting of hydrogen, halogen, cyano, NO2, trifluoromethyl, optionally substituted aryl and optionally substituted heterocyclil;
A represents —S—, —SO—, —SO2—, and n=0-1;
B represents —(CH2)k—R5, where k=0-2, and where R5 is an optionally substituted aryl, an optionally substituted alkyl, an optionally substituted oxyalkyl, or an optionally substituted heterocyclil, or where R5 represents a substituent of the type:
where Rn1 and Rn2 are defined according to the definitions of the substituents R′ and R″ above;
or hydrates and/or pharmaceutically acceptable salts thereof.

### Claim 38 (depends on 37)

A method according to claim 37, wherein the compound of formula (I) is the 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-bromoindole hydrochloride represented by the following formula:
*HCI*H2O.

### Claim 39 (depends on 37)

A method according to claim 37, wherein the compound of formula (I) is the 1-methyl-2-pyrrolidinyl-1-methyl-3-carbethoxy-5-hydroxy-6-(pyridine-3-yl) indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 40 (depends on 37)

A method according to claim 37, wherein the compound of formula (I) is the 1-methyl-2-pyrrolidinomethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-(pyridine-3-yl) indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 41 (depends on 37)

A method according to claim 37, wherein the compound of formula (I) is the 1-methyl-2-dimethylaminomethyl-3-carbethoxy-4-pyrrolidinomethyl-5-hydroxy-6 (pyridine-3-yl) indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 42 (depends on 37)

A method according to claim 37, wherein the compound of formula (I) is the methyl-2-B-naphthylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-bromo indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 43 (depends on 37)

A method according to claim 37, wherein the compound of formula (I) is the 9-carbethoxy-2,7-dimethyl-5-pyridine-3-yl-8-[(pyrrolidin-1-yl)methyl]-1,2,3,7-tetrahydro[1,3]oxazino[5,6-e]indole represented by the following formula:
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 44 (depends on 37)

A method according to claim 37, wherein the compound of formula (I) is selected from the group consisting of:
1-methyl-2-phenylsulfomethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-bromoindole,
1-methyl-2-phenylsulfoxymethyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxy-6-bromoindole,
1-methyl-2-phenylsulfomethyl-3-carbethoxy-5-hydroxy-6-bromoindole,
1-methyl-2-phenylsulfoxymethyl-3-carbethoxy-5-hydroxy-6-bromoindole,
or pharmaceutically acceptable salts and/or hydrates thereof.

### Claim 45 (depends on 37)

A method according to claim 37 wherein said pharmaceutical composition is formulated in the form of tablets, granules, capsules, suspensions, solutions or injections.
